Enlivex stock price target raised to $7 at H.C. Wainwright

Published 24/03/2025, 12:32
© Enlivex Therapeutics PR

On Monday, H.C. Wainwright analyst Raghuram Selvaraju increased the price target for Enlivex Therapeutics (NASDAQ:ENLV) to $7.00, up from the previous $6.00, while maintaining a Buy rating on the stock. Currently trading at $1.04, the company’s stock has seen a challenging year, declining over 70% in the past 12 months according to InvestingPro data. Analyst consensus remains bullish, with price targets ranging from $6.00 to $13.00. The adjustment follows Enlivex’s recent announcement last week regarding a significant development in its patent portfolio.

Enlivex reported that the China National Intellectual Property Administration (CNIPA) had issued a notice of allowance for its patent application numbered 2020800620493. This patent, once granted, is set to bolster the company’s intellectual property rights in China through at least 2040. The patent covers the use of Allocetra, Enlivex’s therapy, for treating patients with osteoarthritis (OA). InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 9.71, while holding more cash than debt on its balance sheet.

The company anticipates the patent will be officially issued in the first half of 2025. According to Selvaraju, the Chinese market is considered highly promising for OA treatment due to the large number of cases present in the country’s vast population. With approximately 130 million cases among China’s 1.4 billion people, OA is recognized as the most prevalent form of arthritis globally.

Osteoarthritis not only affects over 32.5 million Americans but also more than 300 million individuals worldwide. The condition is particularly common following anterior cruciate ligament (ACL) injuries, with about half of such cases developing OA within a span of five to fifteen years. The lifetime risk of developing symptomatic knee OA is substantial, with 40% of men and 47% of women likely to suffer from it.

In the United States alone, OA is responsible for over one million hospitalizations each year, primarily due to total joint replacement surgeries. With this backdrop, Enlivex’s progress in securing intellectual property protection for Allocetra in a key market like China is a significant step for the company. Selvaraju reaffirms the Buy rating for Enlivex and emphasizes the potential of the Chinese market in the firm’s decision to raise the price target. According to InvestingPro, the stock appears undervalued based on its Fair Value analysis, though investors should note that the company is currently unprofitable with an EBITDA of -$15.44M in the last twelve months. For deeper insights into Enlivex’s financial health and growth prospects, including 8 additional ProTips, subscribers can access the full analysis on InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.